Rita Johnson-Greene

Rita Johnson-Greene is currently a Board Member at Public Health Management Corporation. Prior to that, they were the Head of Luxturna, East Zone - US Business at Spark Therapeutics, Inc. from January 2019 to May 2021. There, they led strategic objectives and revenue forecast for Luxturna (RPE65 gene therapy treatment) in the US. Rita also set the strategy for a matrixed zone team, comprised of Medical, Market Access, Patient Services, Genetic Diagnostics, Marketing, and Commercial Operations team members.

Additionally, Rita Johnson-Greene was the Sr. Director of Commercial Operations at Spark Therapeutics, Inc. from November 2016 to November 2018 and the Commercial Business Director - Philadelphia Region at AstraZeneca from January 2007 to November 2016.

Rita Johnson-Greene began their career as an MBA Management Associate (Leadership Rotational Program) at McNeil Consumer Healthcare from August 2003 to January 2007.

Rita Johnson-Greene has a MBA in finance from The Wharton School and a bachelor's degree in electrical engineering from Drexel University.